COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.
J Clin OncolAug 12, 2026 (epub)
Clinical ResearchOncology (Medical)
Antoni Ribas, Caroline Robert, Dirk Schadendorf et al.
✦ AI-curated · Sources linked
In 30 seconds
The COMBI-I trial, a randomized controlled trial, assessed the efficacy of spartalizumab combined with dabrafenib and trametinib in 267 patients with BRAF V600-mutant advanced melanoma. The study found a median overall survival of 61.5 months for the combination therapy compared to 41.6 months for the placebo group, with a hazard ratio of 0.760.
Key findings
- Median overall survival was 61.5 months for sparta-DabTram versus 41.6 months for placebo-DabTram.
- Hazard ratio for overall survival was 0.760 (95% CI, 0.598 to 0.966).
- 65.9% of patients in the sparta-DabTram arm experienced pyrexia as a treatment-related adverse event.
- Grade ≥3 treatment-related adverse events occurred in 57.3% of the sparta-DabTram group.
Why it matters
This study highlights the potential for improved overall survival in patients with BRAF V600-mutant metastatic melanoma when treated with the combination of spartalizumab, dabrafenib, and trametinib, which may influence treatment decisions.